The purchase price for all shares amounted to approximately MUSD 72, including an adjustment of approximately MUSD 4 for net cash and deviation from normalized working capital, of which approximately MUSD 13.6 was paid in 284,176 newly issued shares of series B in CELLINK at a price of 405.75 SEK per share (the “Consideration Shares”) and the reminder in cash. The price for the Consideration Shares has been determined by the weighted average closing price of CELLINK shares of series B on Nasdaq Stockholm three trading days preceding and three trading days post the signing date, i.e., on March 10, 2021. The Consideration Shares are expected to be registered by the Swedish Companies Registration Office during the month of March and will correspond to approximately 0.5 percent of the share capital and approximately 0.4 percent of the votes in CELLINK.
“With this strategic acquisition of MatTek, we further realize CELLINK’s and the founders’ vision to reduce, and in some cases eliminate, animal testing by providing alternative test models. By combining CELLINK and MatTek’s revolutionary technologies, we can offer market-leading in-vitro methods and finally replace controversial animal tests that are limited by their physiological relevance to predict human results. We see several strong synergies in combining CELLINK’s cutting-edge, bioprinting technology and modular large-scale industrial robotic flows with MatTek’s 3D reconstructed, human-derived tissue models creating a world-leading tissue model offering, which are based on decades of research, creating the largest library of 3D human tissue and disease models in the world.” Erik Gatenholm, CEO, CELLINK.
For further information on the acquisition and about MatTek, please see the press release which was published on March 10, 2021.
For further information, please contact:
|Erik Gatenholm, CEO
Phone (Sweden): +46 73 267 00 00
Phone (US): +1 (650) 515 5566
Email: [email protected]
|Gusten Danielsson, CFO
Phone (Sweden): +46 70 991 86 04
Phone (US): +1 (857) 332 2138
Email: [email protected]
The information was submitted for publication, through the agency of the contact persons set out above, on March 22, 2021 at 17:15 (CET).
Founded in 2016, CELLINK is the leading bioconvergence company in the world that provides technologies, products and services to create, understand and master biology. With a focus on the application areas of bioprinting, multiomics, cell line development, and diagnostics, the company develops and markets innovative technologies that enable researchers in the life sciences to culture cells in 3D, perform high-throughput drug screening and print human tissues and organs for the medical, pharmaceutical, and cosmetic industries. CELLINK’s products are trusted by more than 1,800 laboratories, including ones at all the top 20 pharmaceutical companies, are being used in more than 65 countries, and have been cited in more than 1,600 publications. CELLINK is creating the future of medicine. CELLINK is listed on the Nasdaq the Stockholm under CLNK B. www.cellink.com/investors